Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Condition: Diffuse Large B-cell Lymphoma Interventions: Drug: Polatuzumab vedotin (PV); Drug: Rituximab; Drug: Hyaluronidase; Drug: Gemcitabine; Drug: Cisplatin; Drug: Dexamethasone; Drug: GCSF Sponsors: UNC Lineberger Comprehensive Cancer Center; Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials